Every treatment begins with a comprehensive consultation to determine whether peptide therapy is appropriate and how it can best support the patients health objectives
Retatrutide produces significant weight loss in individuals with obesity and type 2 diabetes
it is often combined with CJC-1295 to amplify GH release through dual-pathway stimulation Tesamorelin is the preferred choice when the primary clinical goal is visceral fat reduction specifically, given the direct CT-scan evidence from phase 3 trials CJC-1295 with or without Ipamorelin may be more appropriate when the goal is broader GH axis augmentation (body composition, recovery, sleep quality) rather than visceral fat reduction as the primary endpoint No head-to-head clinical trials have directly compared Tesamorelin to CJC-1295 or Ipamorelin
"Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty"
Wang Z, Lu Z, Lin S, Xia J, Zhong Z, Xie Z, et al
The complexes of SP1 and DNA were separated by immunoprecipitation with antibodies to SP1, protein A, and the target sequences of SP1-bound DNA were amplified by PCR
